Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Anemia And Other Blood Disorder Drugs Market Growth Analysis: How Will Revenue Trend Over The Forecast Period?
The anemia and other blood disorder drugs market has shown robust growth over recent years. Its size is expected to increase from $12.46 billion in 2025 to $13.14 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.5%. This market’s past expansion can be linked to several factors, including the frequent occurrence of iron deficiency anemia, the prevalence of chronic kidney disease, the necessity of blood transfusions, the sustained application of ESAs, and the adoption of established hematology treatment protocols.
The anemia and other blood disorder drugs market is anticipated to experience substantial expansion in the coming years. It is projected to reach $16.88 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.5%. This projected growth is driven by factors such as the increasing adoption of gene therapy, a growing aging population, heightened awareness of blood disorders, the establishment of more specialty hematology clinics, and enhanced diagnostic rates. Key developments expected during this forecast period encompass a rising incidence of chronic blood disorders, a greater reliance on injectable therapies, the broader application of gene therapy for rare anemias, an increased emphasis on personalized hematology treatments, and better availability of crucial blood disorder medications.
Get A Free Sample Report With In-Depth Market Insights:
Anemia And Other Blood Disorder Drugs Market Development Factors: What’s Supporting Demand?
The increasing need for individualized healthcare approaches is anticipated to fuel the expansion of the anemia and other blood disorder drugs market in the future. This medical strategy, known as personalized medicine, utilizes a person’s unique genetic information to inform choices regarding disease prevention, identification, and therapy. The heightened call for personalized medicine stems from its capacity to provide highly effective, specific treatments, leading to better patient results and enduring well-being. Within the anemia and other blood disorder drugs market, personalized care is facilitated through customized treatment strategies that target distinct genetic or molecular traits of these conditions. For example, data from May 2024, provided by the American Psychiatric Association, a US-based non-profit entity, indicates that 43% of adults reported increased anxiety compared to the previous year, rising from 37% in 2023 and 32% in 2022. Consequently, the expanding requirement for personalized medicine is stimulating the development of the anemia and other blood disorder drugs market.
Anemia And Other Blood Disorder Drugs Market Segment Landscape: Which Areas Lead Development?
The anemia and other blood disorder drugs market covered in this report is segmented –
1) By Type: Iron Deficiency Anemia, Chronic Kidney Disease Anemia, Sickle Cell Anemia, Aplastic Anemia
2) By Route of Administration: Oral, Injectable
3) By Distribution Channel: Hospitals Pharmacy, Online Pharmacy, Pharmacy
Subsegments:
1) By Iron Deficiency Anemia: Oral Iron Supplements, Injectable Iron Supplements, Iron Fortified Foods
2) By Chronic Kidney Disease Anemia: Erythropoiesis-Stimulating Agents (ESAs), Iron Supplements, Blood Transfusion
3) By Sickle Cell Anemia: Hydroxyurea, Blood Transfusions, Gene Therapy, Pain Management Drugs
4) By Aplastic Anemia: Immunosuppressive Therapy, Stem Cell Transplantation, Erythropoiesis-Stimulating Agents (ESAs)
Anemia And Other Blood Disorder Drugs Market Transformation Trends: What Innovations Are Driving Change?
Leading companies in the anemia and other blood disorder drugs market are concentrating on introducing innovative medications to enhance therapeutic results, broaden treatment possibilities, and strengthen their competitive standing. Novel medications are defined as advanced pharmaceutical therapies that present new mechanisms of action, superior effectiveness, or improved safety profiles compared to existing treatments, addressing unmet needs in conditions such as anemia and myelodysplastic syndromes. For example, in August 2023, Bristol-Myers Squibb Company, a US-based pharmaceutical company, obtained FDA approval for Reblozyl for the first-line treatment of anemia in adults with lower-risk myelodysplastic syndromes. This marked the first therapy to demonstrate superiority over an erythropoiesis-stimulating agent in this specific setting, supported by Phase 3 COMMANDS trial data revealing that nearly twice as many Reblozyl-treated patients achieved at least 12 weeks of transfusion independence with concurrent hemoglobin improvement compared to those receiving Epoetin alfa.
Anemia And Other Blood Disorder Drugs Market Industry Leaders And Competitive Landscape
Major companies operating in the anemia and other blood disorder drugs market are Amgen Inc, GlaxoSmithKline plc, Akebia Therapeutics Inc., Bayer AG, Pfizer Inc, F. Hoffmann-La Roche Ltd., Merck Sharp & Dohme Corp., Novartis AG, Global Blood Therapeutics Inc., Eli Lilly and Company, FibroGen Inc., bluebird bio Inc., Acceleron Pharma Inc., AMAG Pharmaceuticals Inc., Vifor Pharma Management Ltd., Sanofi S.A., AbbVie Inc., Johnson & Johnson, Daiichi Sankyo Company Limited, Pharmacosmos A/S, Emmaus Medical Inc., Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, Merck & Co. Inc., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Alexion Pharmaceuticals Inc., Grifols S.A.
View The Full Anemia And Other Blood Disorder Drugs Market Report:
Anemia And Other Blood Disorder Drugs Market Regional Breakdown: Where Is Demand Concentrated?
North America was the largest region in the anemia and other blood disorder drugs market in 2025. Middle East is expected to be the fastest-growing region in the anemia and other blood disorder drugs market during the forecast period. The regions covered in the anemia and other blood disorder drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model